<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321489</url>
  </required_header>
  <id_info>
    <org_study_id>TEU-SIL-05/09</org_study_id>
    <nct_id>NCT01321489</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies</brief_title>
  <official_title>A Clinical Phase III, Comparative, Open, Multicenter, Prospectively, to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet, Compared to Viagra ® 50mg Tablet Coated, in the Treatment of Erectile Dysfunction of Different Etiologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratório Teuto Brasileiro S/A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratório Teuto Brasileiro S/A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and safety of Sildenafil Citrate
      20mg Sublingual tablet, as well as a possible superiority expressed by the faster onset of
      action compared to Viagra ® 50mg tablet Coated in erectile dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III clinical trial, comparative, open, multicenter, prospectively, with random inflow
      of 78 patients evaluable male patients with erectile dysfunction with IIEF-5 score in between
      13 and 24, corresponding to mild or mild to moderate to evaluate the efficacy and safety as
      well as a possible superiority expressed by the faster onset of action onset of action of
      study medication.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate a possible superiority expressed by the faster onset of action.</measure>
    <time_frame>35 days</time_frame>
    <description>To evaluate a possible superiority expressed by the faster onset of action of Sildenafil Citrate 20mg Tablet Sublingual compared to Viagra ® 50mg tablet Coated in erectile dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy and tolerability of Sildenafil Citrate 20mg Sublingual tablet, compared to Viagra ® 50mg tablet Coated in control of Erectile Dysfunction.</measure>
    <time_frame>35 days</time_frame>
    <description>The secondary outcame measure will be to evaluate the efficacy and tolerability of Sildenafil Citrate 20mg Sublingual tablet, compared to Viagra ® 50mg tablet Coated in patients with Erectile Dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Sildenafil Citrate 20mg Tablet Sublingual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viagra ® 50mg tablet Coated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate 20mg Tablet Sublingual</intervention_name>
    <description>Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.</description>
    <arm_group_label>Viagra ® 50mg tablet Coated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viagra ® 50mg tablet Coated</intervention_name>
    <description>Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.</description>
    <arm_group_label>Sildenafil Citrate 20mg Tablet Sublingual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years;

          -  Patients with erectile dysfunction of various etiologies (organic, psychogenic and
             mixed) for at least 6 months;

          -  Patients with scores in the IIEF-5 between 13 and 24, which correspond to mild or mild
             to moderate;

          -  Relationship stable for at least 6 months;

          -  Patients should be kept with libido;

          -  Education at least 4 years;

          -  Do not use sildenafil, vardenafil, tadalafil, lodenafil, injection therapy or vacuum
             devices up to 72 hours before the screening visit;

          -  Functions hepatic, hematological, hormonal and renal within the following benchmarks:

          -  Creatinine: 0.6 to 1.10 mg / dl;

          -  Urea: 10 - 50mg/dl;

          -  TGP: up to 40 U / L;

          -  TGO: ≤ 34 U / L;

          -  Prolactin: 2.3 to 11.5 ng / ml Men

          -  Total Testosterone: 241 to 827 ng/100 ml - Men

          -  Blood glucose: 70 mg / dl and 99mg/dl.

        Exclusion Criteria:

          -  Patients who have failed treatment with inhibitors of phospho-diesterase inhibitors;

          -  Patients undergoing radical prostatectomy;

          -  Patients with hypersensitivity to any component of the formula;

          -  Presence of genital deformities or other disorders that prevent intercourse;

          -  Operations prior to penile erectile dysfunction or premature ejaculation penis
             enlargement;

          -  Use of other treatments for erectile dysfunction or concomitant treatment with
             nitrates;

          -  Myocardial infarction or cerebrovascular accident (CVA) for less than 6 months;

          -  Heart disease or uncontrolled serious;

          -  Injury cord injury;

          -  Multiple sclerosis;

          -  Retinitis pigmentosa;

          -  Neoplasms known in business and / or treatment;

          -  History of severe anaphylactic reactions and disease Steven-Johnson;

          -  Participation in a clinical study in the 2 months prior to inclusion;

          -  Patients who are making use of antiretrovirals;

          -  Any other disease or condition is not matched that in the opinion of the investigator,
             could lead to increased risk for the patient or who makes it inappropriate for this
             study;

          -  Comorbidities such as diabetes mellitus, malignant hypertension, blood pressure (BP),
             systolic&gt; 170 mmHg, diastolic BP levels&gt; 110 mmHg, blood pressure &lt;80 x 50 mmHg,
             significant cardiovascular disease, alcohol or drugs, or other disorders important.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Bertero, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for State Civil Servants of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sidney Glina, Investigator</last_name>
    <phone>55 (11) 2069-9629</phone>
    <email>urohi@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bluette Sandila, Coordenator</last_name>
    <phone>55 (11) 2069-9629</phone>
    <email>bluette.urohi@uol.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ipiranga Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04262-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sidney Glina, Investigator</last_name>
      <phone>55 (11) 2069-9629</phone>
      <email>urohi@uol.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Bluette Sandila, Coordenator</last_name>
      <phone>55 (11) 2069-9629</phone>
      <email>bluette.urohi@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Sidney Glina, Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Laboratório Teuto Brasileiro S/A</name_title>
    <organization>Industry</organization>
  </responsible_party>
  <keyword>Phase III</keyword>
  <keyword>Sildenafil Citrate Tablet Sublingual</keyword>
  <keyword>Erectile dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

